Crizotinib, a kinase inhibitor with specificity for ALK, ROS1, and MET, was the first ALK inhibitor evaluated for clinical use and received accelerated FDA approval for treatment of ALK rearranged NSCLC based on an overall response rate of 57% in these patients [2, 8]. This evidence concerns the gene ALK and non-small cell lung carcinoma.